- the Drug Information Association’s 4th Annual China Meeting, at the Shanghai International Convention Center, and
- the Society for Clinical Trials 33rd Annual Meeting in Miami.
“As the environment for clinical research rapidly evolves in China, so does the adoption of OpenClinica and electronic data capture technology,” said Ben Baumann, OpenClinica, LLC’s Co-Founder and Chief Operating Officer. “China holds tremendous potential to be a major contributor to global biomedical research, and we are proud to be a part of this transformation.”
This theme of this year’s event is “collaboration and innovation in China.” Sessions feature numerous topics related to China and global pharmaceuticals. The OpenClinica exhibit will showcase how OpenClinica is leading the way for modern clinical research in China. More information at http://www.openclinica.cn.
Simultaneous with the DIA China event, OpenClinica will be both exhibiting and presenting at this year’s Society for Clinical Trials Annual Meeting in Miami, Florida. On Wednesday, May 23, OpenClinica’s, CEO, Cal Collins, will lead a presentation showcasing an innovative new OpenClinica mobile data capture technology. The session is titled “Electronic Patient Reported Data for Risk Screening in Primary Care Clinics using OpenClinica and CDISC ODM.”
About OpenClinica, LLC
OpenClinica, LLC enhances the productivity of clinical trials through commercial open source software. Trusted by hundreds of biopharmaceutical companies, contract research organizations, academic, and government organizations worldwide, the OpenClinica software facilitates electronic data capture and data management, increasing the speed of collection and quality of data in clinical trials. OpenClinica supports HIPAA, 21 CFR Part 11, and other regulatory guidelines and is designed as a standards-based, extensible, and modular platform. For more information – including product downloads – visit http://www.openclinica.com or follow @OpenClinica on Twitter.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/5/prweb9527081.htm